Axonal changes in chronic demyelinated cervical spinal cord plaques

Brain

Volumn 123, Issue 2, 2000, Pages 308-317

  Lovas, Gábor ^a   Szilágyi, Nóra ^b   Majtényi, Katalin ^a   Palkovits, Miklós ^a   Komoly, Sámuel ^a,c  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

Author keywords

Axonal loss; Multiple sclerosis; Neurofilament 200 kDa immunostaining; Spinal cord

Indexed keywords

ARTICLE; CERVICAL SPINAL CORD; CLINICAL ARTICLE; DEMYELINATING DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; MULTIPLE SCLEROSIS; NERVE FIBER; NERVE FIBER DEGENERATION; NORMAL HUMAN; PRIORITY JOURNAL; WHITE MATTER;

EID: 0342288638     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.2.308     Document Type: Article

References (61)

1. Adams JH, Graham DI, Gennarelli TA, Maxwell WL. Diffuse axonal injury in non-missile head injury [editorial]. [Review]. J Neurol Neurosurg Psychiatry 1991; 54: 481-3.
2. Arnold DL. Reversible reduction of N-acetylaspartate after acute central nervous system damage [abstract]. Proceedings of the Eleventh Annual Meeting of the Society for Magnetic Resonance in Medicine 1992; 1: 643.
3. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36: 76-82.
4. Arnold DL, Wolinsky JS, Matthews PM, Falini A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. [Review]. J Neurol Neurosurg Psychiatry 1998; 64 Suppl 1: S94-101.
5. Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain 1991; 114: 1271-80.
6. Barron KD, Dentinger MP, Csiza CK, Keegan SM, Mankes R. Abnormalities of central axons in a dysmyelinative rat mutant. Exp Mol Pathol 1987; 47: 125-42.
7. Barson AJ, Sands J. Regional and segmental characteristics of the human adult spinal cord. J Anat 1977; 123: 797-803.
8. Charcot JM. Histologie de le sclerose en plaques. Gaz Hop (Paris) 1868; 41: 554-5, 557-8, 566.
9. Dahl D. Immunohistochemical differences between neurofilaments in perikarya, dendrites and axons. Immunofluorescence study with antisera raised to neurofilament polypeptides (200K, 150K, 70K) isolated by anion exchange chromatography. Exp Cell Res 1983; 149: 397-408.
10. Dahl D, Labkovsky B, Bignami A. Early and late appearance of neurofilament phosphorylation events in nerve regeneration. Brain Res Bull 1989; 22: 225-32.
11. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
12. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583-92.
13. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34: 721-7.
14. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS. et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469-77.
15. de Waegh SM, Lee VMY, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 1992; 68: 451-63.
16. Duncan JS. Magnetic resonance spectroscopy. [Review]. Epilepsia 1996; 37: 598-605.
17. England JD, Gamboni F, Levinson SR, Finger TE. Changed distribution of sodium channels along demyelinated axons. Proc Natl Acad Sci USA 1990; 87: 6777-80.
18. Falini A, Calabrese G, Filippi M, Origgi D, Lipari S, Colombo B, et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR Am J Neuroradiol 1998; 19: 223-9.
19. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
20. Filippi M, Campi A, Colombo B, Pereira C, Martinelli V, Baratti C, et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996; 243: 502-5.
21. Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J Neuroimaging 1997; 7: 78-80.
22. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121: 103-13.
23. Ganter P, Prince C, Esiri MM. Spinal cord axon loss in multiple sclerosis: a post mortem study [abstract]. Multiple Sclerosis 1998; 4: 272.
24. Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW. Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 1993; 160: 139-44.
25. Hess CW, Mills KR, Murray NM. Measurement of central motor conduction in multiple sclerosis by magnetic brain stimulation. Lancet 1986; 2: 355-8.
26. 1H spectroscopic imaging. Ann Neurol 1994; 36: 157-65.
27. Ingram DA, Thompson AJ, Swash M. Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J Neurol Neurosurg Psychiatry 1988; 51: 487-94.
28. Lee MK, Cleveland DW. Neuronal intermediate filaments. [Review]. Annu Rev Neurosci 1996; 19: 187-217.
29. Lee VM, Carden MJ, Trojanowski JQ. Novel monoclonal antibodies provide evidence for the in situ existence of a nonphosphorylated form of the largest neurofilament subunit. J Neurosci 1986; 6: 850-8.
30. Lee VM, Carden MJ, Schlaepfer WW, Trojanowski JQ. Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats. J Neurosci 1987; 7: 3474-88.
31. Losseff NA, Miller DH. Measures of brain and spinal cord atrophy in multiple sclerosis. [Review]. J Neurol Neurosurg Psychiatry 1998; 64 Suppl 1: S102-5.
32. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119: 701-8.
33. Losseff NA, Miller DH, McDonald WI, Thompson AJ. T1 hypointensity, disability, and atrophy of the spinal cord in multiple sclerosis [abstract]. J Neurol Neurosurg Psychiatry 1997; 63: 271.
34. Mata M, Kupina M, Fink DJ. Phosphorylation-dependent neurofilament epitopes are reduced at the node of Ranvier. J Neurocytol 1992; 21: 199-210.
35. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991; 41: 1251-6.
36. McDonald WI. Rachelle Fishman-Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. [Review]. J Neuropathol Exp Neurol 1994; 53: 338-43.
37. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. [Review]. Neuropathol Appl Neurobiol 1992; 18: 319-34.
38. 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. [Review]. NMR Biomed 1991; 4: 47-52.
39. Moll C, Ulrich J. Ion channels in MS-plaques. Schweiz Arch Neurol Psychiatr 1989; 140: 27-9.
40. Moll C, Mourre C, Lazdunski M, Ulrich J. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res 1991; 556: 311-6.
41. Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997; 41: 385-91.
42. Nixon RA. The regulation of neurofilament protein dynamics by phosphorylation: clues to neurofibrillary pathobiology. [Review]. Brain Pathol 1993; 3: 29-38.
43. Nixon RA, Brown BA, Marotta CA. Post-translational modification of a neurofilament protein during axoplasmic transport: implications for regional specialization of CNS axons. J Cell Biol 1982; 94: 150-8.
44. Nixon RA, Paskevich P, Sihag RK, Wheelock T. Morphologic correlates of neurofilament carboxyl terminal phosphorylation [abstract]. J Cell Biol 1991; 115 (3 Pt 2): 356a.
45. Palkovits M, Magyar P, Szentágothai J. Quantitative histological analysis of the cerebellar cortex in the cat. I. Number and arrangement in space of the Purkinje cells. Brain Res 1971; 32: 1-13.
46. Patel TB, Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979; 184: 539-46.
47. Peters G. Multiple sclerosis. In: Minckler J, editor. Pathology of the nervous system. New York: McGraw-Hill; 1968. p. 821-43.
48. Prineas JW, Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978; 28: 68-75.
49. Prineas JW, McDonald WI. Demyelinating diseases. In: Graham DI, Lantos P, editors. Greenfield's neuropathology. 6th ed. London: Arnold Press; 1997. p. 813-96.
50. Putnam TJ. Studies in multiple sclerosis. Arch Neurol Psychiatry 1936; 35: 1289-308.
51. Raine CS, Cross AH. Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 1989; 60: 714-25.
52. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
53. Scolding N, Franklin R. Axon loss in multiple sclerosis. Lancet 1998; 352: 340-1.
54. Sherriff FE, Bridges LR, Gentleman SM, Sivaloganathan S, Wilson S. Markers of axonal injury in post mortem human brain. Acta Neuropathol (Berl) 1994; 88: 433-9.
55. Shintaku M, Hirano A, Llena JF. Increased diameter of demyelinated axons in chronic multiple sclerosis of the spinal cord. Neuropathol Appi Neurobiol 1988; 14: 505-10.
56. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
57. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. [Review]. Curr Opin Neurol 1997; 10: 186-92.
58. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
59. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992; 59: 55-61.
60. Vabnick I, Messing A, Chiu SY, Levinson SR, Schachner M, Roder J, et al. Sodium channel distribution in axons of hypomyelinated and MAG null mutant mice. J Neurosci Res 1997; 50: 321-36.
61. Yao DL, Komoly S, Zhang QL, Webster HD. Myelinated axons demonstrated in the CNS and PNS by anti-neurofilament immunoreactivity and Luxol fast blue counterstaining. Brain Pathol 1994; 4: 97-100.